The GLP-1 Activity Trap: Why Ozempic Users Are Moving Less — And What It Means for Your Health

The promise of GLP-1 medications has been straightforward: take the drug, lose the weight, feel better, move more. The last part turned out to be wrong. Research presented at ENDO 2026 — the Endocrine Society's annual scientific meeting — found that adults with obesity who started GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound walked an average of 560 fewer steps per day after beginning treatment. Their moderate-to-vigorous physical activity declined from 27.9 minutes per day to 22.2 minutes. They lost weight, yes. But they became more sedentary in the process.

This is not a fringe finding from a small study. The research — led by Dr. Sajana Maharjan and colleagues — drew on the All of Us Research Program, using Fitbit activity data from 753 adults with obesity who had reliable pre- and post-treatment records. The dataset is one of the largest real-world analyses of physical activity and GLP-1 therapy published to date. And what it shows has significant implications for the estimated 15 million Americans currently using these medications — most of whom are moving through their treatment with no exercise protocol, no resistance training guidance, and no warning that the drug's weight-loss mechanism may be quietly accelerating one of aging's most damaging processes: the loss of lean muscle mass.

What the Research Found: 560 Fewer Steps Per Day

The Fitbit data tells a precise story. Before starting GLP-1 therapy, study participants averaged 5,047 steps per day. After initiation, that number fell to 4,487 — a statistically significant decline of roughly 11% (P < 0.001). Moderate-to-vigorous physical activity, the category of movement that provides most of the cardiovascular and metabolic benefit, dropped from approximately 27.9 minutes to 22.2 minutes per day. That six-minute daily reduction may sound modest. Compounded over the 36-to-52 weeks of a typical GLP-1 treatment course, it represents a meaningful reduction in the cardiovascular stimulus the body receives during the very period when weight loss is most rapid — and when maintaining metabolic rate matters most.

The decline was not uniform across the study population. Men reduced their daily step count by 986 steps on average, more than double the 445-step decline seen in women. Patients with musculoskeletal pain also showed steeper drops than those without. Those subgroup differences matter clinically, because they identify who most needs an exercise protocol alongside the prescription rather than after it.

The study was presented at ENDO 2026 in June and covered by the Endocrine Society's news office, but received comparatively little attention from health media focused on GLP-1 drugs. Coverage of these medications overwhelmingly emphasizes weight loss percentages, new approvals, and the expanding list of conditions they may treat. The behavioral and musculoskeletal consequences of reduced activity during treatment are a less commercially convenient story. Which is precisely why the millions of people currently on these drugs need to understand the data.

Why GLP-1 Users Move Less: The Biology

The activity decline is not primarily a motivation problem. It reflects the drug's mechanism acting more broadly than its primary targets. GLP-1 receptors are present not only in the gut and pancreas — where they reduce appetite and regulate blood sugar — but also in regions of the brain that govern impulse control, reward signaling, and motivation. Research has found that GLP-1 medications reduce pleasure-seeking behaviors triggered by addictive substances, an effect that may extend to the reward loop associated with physical activity. In the early weeks of treatment, nausea and caloric restriction fatigue compound the effect, creating a recovery dynamic that makes rest feel physiologically preferable to movement.

The Muscle Loss Problem Nobody Warned You About

Physical activity reduction matters most because of what is happening to body composition during GLP-1 treatment. These medications produce significant weight loss — an average of 10-15% of body weight with semaglutide, and higher with tirzepatide in clinical trials. But that weight is not all fat. Estimates from multiple randomized controlled trials suggest that 20-40% of GLP-1 weight loss comes from lean tissue, including skeletal muscle. For a person losing 40 pounds, that could mean 8 to 16 pounds of muscle lost alongside the fat.

The long-term implications are serious. Skeletal muscle is the body's primary site of glucose disposal — the tissue that absorbs blood sugar after meals and that drives resting metabolic rate. Losing it reduces how many calories the body burns at rest, increases the risk of weight regain after stopping the drug, and accelerates what clinicians call sarcopenia: the age-related loss of muscle that drives frailty, fall risk, and functional decline in aging adults. For the patients most commonly prescribed GLP-1 medications — middle-aged adults with obesity and metabolic disease — muscle loss is not a cosmetic concern. It is a clinical one.

• 20-40% of GLP-1 weight loss is lean tissue rather than fat, across multiple randomized controlled trials
• Absolute muscle mass declines even when the ratio of lean mass to total body weight appears to hold steady
• Skeletal muscle loss increases the risk of weight regain after discontinuing GLP-1 therapy, as metabolic rate falls
• Adults over 50 starting GLP-1 therapy are already in the highest-risk demographic for age-related muscle loss
• The ENDO 2026 study found physical activity — the primary protection against lean tissue loss — is declining, not increasing, on GLP-1 therapy

What Exercise and Protein Actually Change

The clinical picture is correctable with a specific protocol — and the evidence for that protocol is now strong. The most important finding from the exercise-and-GLP-1 literature is not that exercise helps. It is that supervised resistance and aerobic training, when combined with GLP-1 therapy and adequate protein intake, produces outcomes that are categorically different from pharmacotherapy alone. In research combining GLP-1 therapy with a supervised exercise program, patients not only achieved superior weight loss but preserved lean mass during treatment — an outcome that the drug alone does not produce. The drug narrows the waist. The weight room decides how much of what remains is muscle.

The protein piece is equally critical and equally underemphasized in most prescribing conversations. Reviews of GLP-1 and musculoskeletal outcomes identify a dietary protein intake of approximately 1.2-1.6 grams per kilogram of body weight per day as the threshold at which lean mass preservation shifts from uncertain to reliable. For a 200-pound (90 kg) person, that is 108-144 grams of protein daily — significantly more than the typical American diet provides and considerably above what most GLP-1 prescribers discuss in a standard clinical consultation.

“The question is not whether to exercise on GLP-1 therapy. The question is whether your prescriber has told you that not exercising may undermine the most important long-term outcomes of the drug — and that the research has a clear protocol for what to do instead.”

Can Pharmacology Close the Gap?

One of the most closely watched developments in GLP-1 research is the combination of semaglutide with bimagrumab, a myostatin inhibitor that blocks the signaling pathway responsible for muscle tissue degradation. In mid-stage trial data, this combination substantially reduced the lean-mass fraction of weight loss compared with GLP-1 therapy alone. If that finding replicates in larger trials, it would represent a significant clinical advance: a pharmacological answer to the muscle-preservation problem that does not depend on patients overcoming the activity-suppressing effects of the drug itself. That evidence is not yet definitive, and it should not be treated as a reason to skip resistance training in the meantime.

A Practical Protocol for GLP-1 Users

The research points toward a clear set of practices that GLP-1 users can implement regardless of whether their prescriber has raised the issue. The foundation is resistance training: two to three sessions per week of compound movements — squats, deadlifts, rows, overhead presses — that stimulate the major muscle groups and create the mechanical stimulus for lean mass preservation. Aerobic exercise on non-resistance days maintains cardiovascular fitness and contributes to the daily activity minutes that the ENDO 2026 study showed declining. Protein intake should be tracked deliberately. For patients dealing with significant nausea in the first four to eight weeks of treatment, holding the pre-treatment baseline of roughly 5,000 steps per day is a realistic and evidence-grounded starting point.

• Do resistance training 2-3 times per week targeting all major muscle groups with compound movements — the single highest-impact intervention
• Track daily protein intake and target 1.2-1.6 grams per kilogram of body weight; do not estimate, measure
• Use your pre-GLP-1 step count as a floor, not a ceiling — the ENDO study shows initiation causes a drop, so maintain it intentionally
• If dealing with nausea in early weeks, prioritize low-intensity walking and protein; add resistance training as tolerance allows
• Ask your prescriber directly about lean mass risk and exercise co-prescription, particularly if you are male or managing musculoskeletal pain

This article is general information, not medical advice. Decisions about starting, stopping, or changing GLP-1 therapy — and about exercise programming while on it — should be made with a clinician who knows your history.